In recent years, there has been a surge in the number of license transactions for innovative drugs and new technologies in China. Despite the financing problem and the trend of globalization, authorization cooperation remains active. In 2022, domestic biopharmaceutical companies disclosed a total of 90 license-in transactions, 52 license-out transactions, and 49 domestic license transactions, with a total transaction value of up to 36.15 billion US dollars. These transactions covered multiple fields such as oncology, autoimmune diseases, and the nervous system.

To assist more companies with their licensing and financing needs and facilitate cooperation agreements, we are proud to announce the launch of the 3rd DJSeedin Innovation Partnering Conference in April 2023. This conference will serve as a global platform for transactions, financing, and partnerships in the field of innovative pharmaceuticals, specifically tailored for Chinese companies. We are now officially entering the project solicitation phase, and we look forward to receiving your submissions. 

More then 70 companies from different development stage will present their pipelines and strategies in the conference.

Last year, more than 600 biotech, pharma, therapeutic R&D, CRO, CDMO, and venture capital&fund in DJSeedin, bring over 1000 pharma executives and investors together to connect and share industry insights.

Our goal is to promote industry transactions and investments, and to provide innovative pharmaceutical companies in China with a global platform for trading, financing, and collaboration. By doing so, we hope to showcase the significant impact of China's biopharmaceutical industry to the world.

Supported by professional conference andone-on-one meeting platform, DJSeedin willbring biotech startups,clinical stage biophar-maceutical companies and public companiesto meet with distinguished investors and BigPharma's BD executives.